| dc.contributor.author | Sakhuja, Rajeev | |
| dc.date.accessioned | 2021-11-11T11:01:14Z | |
| dc.date.available | 2021-11-11T11:01:14Z | |
| dc.date.issued | 2013-09 | |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0028390813001974 | |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/3380 | |
| dc.description.abstract | Desired serotonin 5HT2 receptor pharmacology for treatment of psychoses is 5HT2A antagonism and/or 5HT2C agonism. No selective 5HT2A antagonist has been approved for psychosis and the only approved 5HT2C agonist (for obesity) also activates 5HT2A and 5HT2B receptors, which can lead to clinical complications. Studies herein tested the hypothesis that a dual-function 5HT2A antagonist/5HT2C agonist that does not activate 5HT2B receptors would be suitable for development as an antipsychotic drug, without liability for weight gain. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Elsiever | en_US |
| dc.subject | Anorectic response | en_US |
| dc.subject | Antipsychotic drug | en_US |
| dc.subject | Binge eating | en_US |
| dc.subject | DOI head-twitch response | en_US |
| dc.title | Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: Potential utility as antipsychotic medication | en_US |
| dc.type | Article | en_US |
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||